These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 16729775)
1. Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline? Lipworth B Ann Allergy Asthma Immunol; 2006 May; 96(5):640-2. PubMed ID: 16729775 [No Abstract] [Full Text] [Related]
2. Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease. Doggrell SA Expert Opin Pharmacother; 2006 Mar; 7(4):485-8. PubMed ID: 16503820 [No Abstract] [Full Text] [Related]
3. Roflumilast for asthma and chronic obstructive pulmonary disease. Cowan C Issues Emerg Health Technol; 2005 Oct; (74):1-4. PubMed ID: 16317827 [TBL] [Abstract][Full Text] [Related]
4. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Karish SB; Gagnon JM Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669 [TBL] [Abstract][Full Text] [Related]
6. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases]. Xia XD; Dai YR; Xu ZJ Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829 [No Abstract] [Full Text] [Related]
7. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Page CP Int Arch Allergy Immunol; 2014; 165(3):152-64. PubMed ID: 25532037 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of roflumilast in the treatment of asthma. Bateman ED; Izquierdo JL; Harnest U; Hofbauer P; Magyar P; Schmid-Wirlitsch C; Leichtl S; Bredenbröker D Ann Allergy Asthma Immunol; 2006 May; 96(5):679-86. PubMed ID: 16729780 [TBL] [Abstract][Full Text] [Related]
11. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease]. Kreutzkamp B Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460 [TBL] [Abstract][Full Text] [Related]
12. The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease. Cazzola M Ther Adv Respir Dis; 2010 Aug; 4(4):195-8. PubMed ID: 20696819 [No Abstract] [Full Text] [Related]
13. Phosphodiesterase inhibitors in airways disease. Fan Chung K Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289 [TBL] [Abstract][Full Text] [Related]
14. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma. Herbert C; Hettiaratchi A; Webb DC; Thomas PS; Foster PS; Kumar RK Clin Exp Allergy; 2008 May; 38(5):847-56. PubMed ID: 18307529 [TBL] [Abstract][Full Text] [Related]
15. Roflumilast for the treatment of chronic obstructive pulmonary disease. Antoniu SA Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716 [TBL] [Abstract][Full Text] [Related]
16. Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model. Harada D; Ikeda Y; Nosaka Y; Kobayashi K; Manabe H J Dermatol Sci; 2008 Sep; 51(3):215-9. PubMed ID: 18539440 [No Abstract] [Full Text] [Related]
17. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Giembycz MA Monaldi Arch Chest Dis; 2002 Feb; 57(1):48-64. PubMed ID: 12174704 [TBL] [Abstract][Full Text] [Related]